Alexion down on Amgen challenge of Soliris patents
Alexion Pharmaceuticals (NASDAQ:ALXN) is down 8% premarket on modest volume in reaction to Amgen’s (NASDAQ:AMGN) challenge of three patents covering top seller Soliris (eculizumab).
The USPTO should announce its decision in about a year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.